Form 4 for PCVX Vaxcyte, Inc.
Accepted 2024-03-20 00:00:00 ET · period of report 2024-03-18 · accession 0001415889-24-008745 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2024-03-20 | 2024-03-18 | PCVX | GUGGENHIME ANDREW | Pres AND CFO | S - Sale+OE | $69.02 | -8,000 | 95.7K | -8% | -$552.2K |
| D | 2024-03-20 | 2024-03-18 | PCVX | GUGGENHIME ANDREW | Pres AND CFO | M - OptEx | $5.35 | +8,000 | 103.7K | +8% | +$42.8K |
| D | 2024-03-20 | 2024-03-18 | PCVX | GUGGENHIME ANDREW | Pres AND CFO | M - OptEx | $0.00 | -8,000 | 368.8K | -2% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-03-18 | S | D | 7,764 | $69.00 | 95,915 | D | — | — | (F2) The price reported is a weighted-average price. The shares were sold at prices ranging from $68.58 to $69.495. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. |
| 2 | Common | Common Stock | 2024-03-18 | S | D | 236 | $69.64 | 95,679 | D | — | — | (F3) The price reported is a weighted-average price. The shares were sold at prices ranging from $69.625 to $69.66. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. |
| 3 | Common | Common Stock | 2024-03-18 | M | A | 8,000 | $5.35 | 103,679 | D | — | — | |
| 4 | Derivative | Stock Option (right to buy) | 2024-03-18 | M | D | 8,000 | $0.00 | 368,827 | D | $5.35 · — to 2030-05-11 | 8,000 Common Stock | (F4) 1/4 of the shares subject to the option vested on May 1, 2021, and 1/48 of the shares vest monthly thereafter. |